Founded in 2014, ARTPred B.V. is a research driven medtech company in the field of IVF. It is our vision is to fundamentally change infertility care worldwide. The mission of ARTPred is to make its unique technology available for all IVF patients. ARTPred has, together with our partners, developed, world’s first validated fertility microbiome profiling test. ReceptIVFity is CE-IVD certified and sold in the E.U. ARTPred is performing new clinical trials to further strengthen our predictive test in other geographical regions and to develop therapeutic interventions that improve the female microbiome and fertility outcome.